Question: 1101 

Evidence: The work described has not been published previously, it is not under consideration for publication elsewhere, and its publication is approved by all authors. We included patients with confirmed HIV infection, currently attending medical controls at Red Salud UC CHRISTUS.

Rationale: The funding/ethics section explicitly states the work had not been previously published. The methods describe a new cohort and sequencing effort, indicating original data.

Answer: Yes


Question: 1102 

Evidence: We could amplify and obtain successful genotypes for RT and PR segment in 15/16 patients (94 %), and in 16/ 16 patients for integrase segment. Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20] for protease (PR), reverse transcriptase (RT) and integrase mutations, and additionally with Geno2pheno for integrase mutations.

Rationale: Successful genotyping and downstream analysis of consensus sequences demonstrate that HIV sequences were obtained and reported.

Answer: Yes


Question: 1103 

Evidence: As RNA genotyping test has a high possibility to deliver inconsistent results in patients with LLV [12], proviral DNA emerges as an alternative to study drug resistance mutations (DRM) in these patients, as this technique does not requires free RNA in plasma [13,14]. After DNA extraction and amplification [19], sequencing was made in Macrogen laboratories (U.S.A) by Sanger method.

Rationale: The study focuses on patient-derived proviral DNA sequencing with no mention of laboratory passaging of virus; there are no in vitro passage experiments described.

Answer: No


Question: 1104 

Evidence: Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20] for protease (PR), reverse transcriptase (RT) and integrase mutations, and additionally with Geno2pheno for integrase mutations. In this study, we found a high rate of mutations in HIV-infected patients with LLV by proviral DNA amplification.

Rationale: The paper reports genotypic resistance interpretation, not novel in vitro phenotypic susceptibility measurements; no IC values or susceptibility assay results are presented.

Answer: No


Question: 2101 

Evidence: After DNA extraction and amplification [19], sequencing was made in Macrogen laboratories (U.S.A) by Sanger method, and analysis was made studying chromatograms ABI in RECall software. Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20] for protease (PR), reverse transcriptase (RT) and integrase mutations, and additionally with Geno2pheno for integrase mutations.

Rationale: The methods describe sequencing and analysis but there is no mention anywhere of depositing sequences in GenBank or providing accession numbers.

Answer: No


Question: 2102 

Evidence: After DNA extraction and amplification [19], sequencing was made in Macrogen laboratories (U.S.A) by Sanger method, and analysis was made studying chromatograms ABI in RECall software. Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20] for protease (PR), reverse transcriptase (RT) and integrase mutations, and additionally with Geno2pheno for integrase mutations.

Rationale: The paper does not report any GenBank accession numbers at all, whether for patient-derived or laboratory isolates.

Answer: No


Question: 2103 

Evidence: After DNA extraction and amplification [19], sequencing was made in Macrogen laboratories (U.S.A) by Sanger method. Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20] for protease (PR), reverse transcriptase (RT) and integrase mutations.

Rationale: No GenBank accession numbers are provided anywhere in the text; therefore none can be listed.

Answer: NA


Question: 2202 

Evidence: Table 1 shows patients characteristics , current and previous ART, reasons of change, CD4 counts, HIV VL, and DRM found in proviral DNA. Eleven patients (68.7 %) had DRM.

Rationale: Table 1 contains per-patient mutations across genes (NRTI/NNRTI/PI/IN), which constitutes lists of mutations for individual sequenced isolates.

Answer: Yes


Question: 2301 

Evidence: We included patients with confirmed HIV infection, currently attending medical controls at Red Salud UC CHRISTUS. In this study, we found a high rate of mutations in HIV-infected patients with LLV by proviral DNA amplification.

Rationale: The paper refers generically to “HIV-infected patients” and does not specify HIV-1 versus HIV-2; species cannot be definitively determined from the provided text.

Answer: NA


Question: 2302 

Evidence: Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20] for protease (PR), reverse transcriptase (RT) and integrase mutations. Table 1 shows patients characteristics , current and previous ART, reasons of change, CD4 counts, HIV VL, and DRM found in proviral DNA.

Rationale: There is no mention of viral subtypes anywhere; therefore subtypes are not reported.

Answer: NA


Question: 2303 

Evidence: Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20] for protease (PR), reverse transcriptase (RT) and integrase mutations, and additionally with Geno2pheno for integrase mutations. We could amplify and obtain successful genotypes for RT and PR segment in 15/16 patients (94 %), and in 16/ 16 patients for integrase segment.

Rationale: The methods and results explicitly list the sequenced genes: protease, reverse transcriptase, and integrase.

Answer: Protease (PR), reverse transcriptase (RT), and integrase (IN)


Question: 2304 

Evidence: Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20] for protease (PR), reverse transcriptase (RT) and integrase mutations. We could amplify and obtain successful genotypes for RT and PR segment in 15/16 patients (94 %), and in 16/ 16 patients for integrase segment.

Rationale: PR, RT, and IN are components of the HIV pol gene; sequencing results for these regions indicate that HIV pol sequences were reported.

Answer: Yes


Question: 2401 

Evidence: We included patients with confirmed HIV infection, currently attending medical controls at Red Salud UC CHRISTUS. This study was authorized by the Ethics Committee of the School of Medicine, Pontificia Universidad Católica de Chile.

Rationale: The clinical site and ethics body indicate the sequences are from Chile.

Answer: Chile


Question: 2402 

Evidence: Samples were taken between September 2018 to March 2019. The analysis of proviral DNA was done on March 2019.

Rationale: The sampling window is explicitly stated, providing the years of sample collection.

Answer: 2018–2019


Question: 2502 

Evidence: After DNA extraction and amplification [19], sequencing was made in Macrogen laboratories (U.S.A) by Sanger method. Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20].

Rationale: The methods explicitly state that sequencing used the Sanger method.

Answer: Yes


Question: 2503 

Evidence: After DNA extraction and amplification [19], sequencing was made in Macrogen laboratories (U.S.A) by Sanger method. Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20].

Rationale: Only Sanger sequencing is mentioned; there is no mention of next-generation sequencing.

Answer: No


Question: 2504 

Evidence: Total blood remnant (in EDTA) were stored at -40 °C until analysis. After DNA extraction and amplification [19], sequencing was made in Macrogen laboratories (U.S.A) by Sanger method.

Rationale: The protocol describes bulk DNA extraction, PCR amplification, and Sanger sequencing of consensus sequences, with no mention of cloning prior to sequencing.

Answer: NA


Question: 2505 

Evidence: After DNA extraction and amplification [19], sequencing was made in Macrogen laboratories (U.S.A) by Sanger method, and analysis was made studying chromatograms ABI in RECall software. Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20].

Rationale: The use of bulk PCR and Sanger consensus sequencing indicates that single-genome sequencing was not performed.

Answer: No


Question: 2506 

Evidence: After DNA extraction and amplification [19], sequencing was made in Macrogen laboratories (U.S.A) by Sanger method. Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20].

Rationale: There is no description of molecular cloning of viral genomes; the approach used direct bulk PCR and Sanger sequencing.

Answer: NA


Question: 2601 

Evidence: As RNA genotyping test has a high possibility to deliver inconsistent results in patients with LLV [12], proviral DNA emerges as an alternative to study drug resistance mutations (DRM) in these patients, as this technique does not requires free RNA in plasma [13,14]. After DNA extraction and amplification [19], sequencing was made in Macrogen laboratories (U.S.A) by Sanger method.

Rationale: The study purposefully avoided plasma RNA genotyping and instead sequenced proviral DNA; no plasma HIV sequencing results are reported.

Answer: No


Question: 2602 

Evidence: Total blood remnant (in EDTA) were stored at -40 °C until analysis. The analysis of proviral DNA was done on March 2019.

Rationale: Sequencing was performed on proviral DNA extracted from whole blood/PBMCs, which corresponds to PBMC-associated HIV sequences.

Answer: Yes


Question: 2603 

Evidence: As RNA genotyping test has a high possibility to deliver inconsistent results in patients with LLV [12], proviral DNA emerges as an alternative to study drug resistance mutations (DRM) in these patients, as this technique does not requires free RNA in plasma [13,14]. We could amplify and obtain successful genotypes for RT and PR segment in 15/16 patients (94 %), and in 16/ 16 patients for integrase segment.

Rationale: The study reports only proviral DNA sequencing; therefore, the number of plasma virus sequences is zero.

Answer: 0


Question: 2604 

Evidence: Ultimately, 16 patients/ samples were included. We could amplify and obtain successful genotypes for RT and PR segment in 15/16 patients (94 %), and in 16/ 16 patients for integrase segment.

Rationale: All included samples underwent proviral DNA sequencing with successful integrase genotyping in all 16, indicating 16 PBMC/proviral DNA sequences.

Answer: 16


Question: 2605 

Evidence: They must have had two or more consecutive values of HIV VL between 20 and 500 copies RNA/mL, from May 2017 to December 2018 and at the moment of the study sampling. The median HIV VL was 49 copies RNA/mL.

Rationale: Participants had detectable plasma viremia (LLV) at sampling, indicating ongoing viral replication.

Answer: Yes


Question: 2606 

Evidence: As RNA genotyping test has a high possibility to deliver inconsistent results in patients with LLV [12], proviral DNA emerges as an alternative to study drug resistance mutations (DRM) in these patients, as this technique does not requires free RNA in plasma [13,14]. The analysis of proviral DNA was done on March 2019.

Rationale: The sequencing was explicitly performed on proviral DNA, i.e., the latent reservoir.

Answer: Yes


Question: 2701 

Evidence: We included patients with confirmed HIV infection, currently attending medical controls at Red Salud UC CHRISTUS. Table 1 shows patients characteristics , current and previous ART, reasons of change, CD4 counts, HIV VL, and DRM found in proviral DNA.

Rationale: The paper does not report ages or specify inclusion of infants/children; thus, this cannot be determined from the text.

Answer: NA


Question: 2702 

Evidence: We included patients with confirmed HIV infection, currently attending medical controls at Red Salud UC CHRISTUS. This study was authorized by the Ethics Committee of the School of Medicine, Pontificia Universidad Católica de Chile.

Rationale: The study is an observational sequencing study of clinic attendees with ethics approval; there is no indication that participants were enrolled in a clinical trial.

Answer: No


Question: 2703 

Evidence: We included patients with confirmed HIV infection, currently attending medical controls at Red Salud UC CHRISTUS. This study was authorized by the Ethics Committee of the School of Medicine, Pontificia Universidad Católica de Chile.

Rationale: Since none were indicated to be in a clinical trial, it follows that not all were in a trial.

Answer: No


Question: 3101 

Evidence: Ultimately, 16 patients/ samples were included. We could amplify and obtain successful genotypes for RT and PR segment in 15/16 patients (94 %), and in 16/ 16 patients for integrase segment.

Rationale: Sixteen individuals had samples included and sequenced (successfully at least for integrase).

Answer: 16


Question: 3102 

Evidence: We could amplify and obtain successful genotypes for RT and PR segment in 15/16 patients (94 %), and in 16/ 16 patients for integrase segment. Samples were taken between September 2018 to March 2019.

Rationale: All 16 had successful integrase genotyping; therefore, all underwent HIV sequencing.

Answer: Yes


Question: 4101 

Evidence: All patients were on ART with two nucleoside reverse transcriptase inhibitor (NRTI) plus an integrase strand transfer inhibitor (INSTI). Patients had been treated on average for 3.3 years.

Rationale: All participants were receiving ART and had treatment history; no ART-naive sequences are reported.

Answer: No


Question: 4102 

Evidence: All patients were on ART with two nucleoside reverse transcriptase inhibitor (NRTI) plus an integrase strand transfer inhibitor (INSTI). Six of them had exposure to more than one HIV treatment regimen.

Rationale: The cohort consists of ART-experienced individuals, some with multiple prior regimens; thus, sequences from ARV-experienced persons are reported.

Answer: Yes


Question: 4103 

Evidence: All patients were on ART with two nucleoside reverse transcriptase inhibitor (NRTI) plus an integrase strand transfer inhibitor (INSTI). Patients had been treated on average for 3.3 years.

Rationale: The study includes only ART-experienced individuals; there are no ART-naive participants.

Answer: No


Question: 4104 

Evidence: All patients were on ART with two nucleoside reverse transcriptase inhibitor (NRTI) plus an integrase strand transfer inhibitor (INSTI). Patients had been treated on average for 3.3 years.

Rationale: Since all are ART-experienced, the number of ART-naive individuals is zero.

Answer: 0


Question: 4105 

Evidence: Table 1 shows patients characteristics , current and previous ART, reasons of change, CD4 counts, HIV VL, and DRM found in proviral DNA. Six of them had exposure to more than one HIV treatment regimen.

Rationale: The paper provides, per individual, current therapy and previous therapy (or none), indicating ART history across the cohort.

Answer: Yes


Question: 4201 

Evidence: Second, we do not make baseline genotyping in our country because transmitted drug resistance (TDR) is about 2.7 % [30]. More recent evidence show TDR between 7.7–11 % in Latin America [31,32].

Rationale: The discussion references external TDR prevalence but does not report TDR prevalence for this study’s cohort.

Answer: No


Question: 4202 

Evidence: Second, we do not make base- line genotyping in our country because transmitted drug resistance (TDR) is about 2.7 % [30]. More recent evidence show TDR between 7.7–11 % in Latin America [31,32].

Rationale: There is no reporting of pretreatment resistance prevalence in this cohort; only external references are provided.

Answer: No


Question: 4301 

Evidence: All patients were on ART with two nucleoside reverse transcriptase inhibitor (NRTI) plus an integrase strand transfer inhibitor (INSTI). Only one of the five patients with NNRTI mutations had history of NNRTI exposure. All of PR mutations were accessory mutations and none of those patients had history of exposure to PI.

Rationale: Current regimens included NRTIs and INSTIs; the paper also discusses NNRTI and PI exposures, indicating these drug classes were received by some individuals historically.

Answer: NRTIs, INSTIs, NNRTIs, and PIs


Question: 4302 

Evidence: All patients were on ART with two nucleoside reverse transcriptase inhibitor (NRTI) plus an integrase strand transfer inhibitor (INSTI). Four out of six patients that showed mutations to INSTI had some mutation that could compromise their current therapy.

Rationale: All patients received integrase inhibitors as part of their current regimens, and INSTI mutations were evaluated.

Answer: Yes


Question: 4303 

Evidence: All of PR mutations were accessory mutations and none of those patients had history of exposure to PI. Table 1 shows patients characteristics , current and previous ART, reasons of change, CD4 counts, HIV VL, and DRM found in proviral DNA.

Rationale: The text explicitly discusses PI exposure histories for individuals, indicating that the paper reports information on PI use; Table 1 lists prior PI-containing regimens.

Answer: Yes


Question: 4304 

Evidence: All patients were on ART with two nucleoside reverse transcriptase inhibitor (NRTI) plus an integrase strand transfer inhibitor (INSTI). Table 1 shows patients characteristics , current and previous ART, reasons of change, CD4 counts, HIV VL, and DRM found in proviral DNA.

Rationale: Although all regimens were two NRTIs plus an INSTI, the specific INSTI and NRTIs varied across individuals (e.g., DTG, RAL, EVG/c; ABC/3TC vs TDF/FTC), so not all received the same ART.

Answer: No


Question: 4305 

Evidence: All patients were on ART with two nucleoside reverse transcriptase inhibitor (NRTI) plus an integrase strand transfer inhibitor (INSTI). Regarding the patients with integrase mutations, all had reduced susceptibility to raltegravir and elvitegravir , and one patient, additionally to dolutegravir (DTG) and bictegravir.

Rationale: The cohort consisted of individuals receiving INSTIs; therefore, they were not INSTI-naive.

Answer: No


Question: 4403 

Evidence: Six of them had exposure to more than one HIV treatment regimen. Table 1 shows patients characteristics , current and previous ART, reasons of change, CD4 counts, HIV VL, and DRM found in proviral DNA.

Rationale: The results state that six individuals had been exposed to more than one regimen.

Answer: 6


Question: 4404 

Evidence: Table 1 shows patients characteristics , current and previous ART, reasons of change, CD4 counts, HIV VL, and DRM found in proviral DNA. 

Rationale: From Table 1, at least one individual (patient 15) is listed with three prior ART regimens, indicating more than two; there is no indication that more than one such case exists.

Answer: 1


Question: 4405 

Evidence: Six of them had exposure to more than one HIV treatment regimen. Table 1 shows patients characteristics , current and previous ART, reasons of change, CD4 counts, HIV VL, and DRM found in proviral DNA.

Rationale: Since only six had more than one regimen and others had none or one previous regimen, the number of regimens varied; therefore, not all received the same number.

Answer: No


Question: 4406 

Evidence: Six of them had exposure to more than one HIV treatment regimen. Table 1 shows patients characteristics , current and previous ART, reasons of change, CD4 counts, HIV VL, and DRM found in proviral DNA.

Rationale: Because several individuals had more than one regimen, not all received exactly one.

Answer: No


Question: 4501 

Evidence: Table 1 shows patients characteristics , current and previous ART, reasons of change, CD4 counts, HIV VL, and DRM found in proviral DNA. All patients were on ART with two nucleoside reverse transcriptase inhibitor (NRTI) plus an integrase strand transfer inhibitor (INSTI).

Rationale: Counting the DTG-containing current regimens in Table 1 (TDF/FTC+DTG and ABC/3TC/DTG) yields 10 individuals.

Answer: 10


Question: 4502 

Evidence: Table 1 shows patients characteristics , current and previous ART, reasons of change, CD4 counts, HIV VL, and DRM found in proviral DNA. zidovudine (AZT), didianosine (DDI), stavudine (D4T), abacavir (ABC), tenofovir (TDF), efavirenz (EFV), doravirine (DOR), rilpivirine (RPV), etravirine (ETR), ne- virapine (NVP), atazanavir/r (ATV/r), fosamprenavir/r (FPV/r), indinavir/r (IDV/r), saquinavir /r (SQV/r) nelfinavir (NFV) and tipranavir/r (TPV/r).

Rationale: Neither the table nor the drug list mentions darunavir (DRV/r) among current or previous regimens, so no individuals received darunavir.

Answer: 0


Question: 5101 

Evidence: Eleven patients (68.7 %) had DRM. Table 1 shows patients characteristics , current and previous ART, reasons of change, CD4 counts, HIV VL, and DRM found in proviral DNA.

Rationale: The results explicitly state the number and proportion of patients with at least one drug resistance mutation.

Answer: 11


Question: 5102 

Evidence: Six out of 16 patients (37, 5%) with integrase genotyping, had some mutation that conferred resistance to one or more ARV of that family. Four out of six patients that showed mutations to INSTI had some mutation that could compromise their current therapy.

Rationale: The paper reports six individuals with INSTI-resistance mutations.

Answer: 6


Question: 5103 

Evidence: All NRTI mutations were TAMs, however just one of these patients have had exposure to AZT and TDF. Table 1: Patient 15 NRTI mutations “Potential low level resistance to ABC and TDF, low level to DDI, intermediate to AZT and D4T”.

Rationale: Only patient 15 is explicitly reported to have TDF resistance (potential low-level), so the count is one.

Answer: 1


Question: 5104 

Evidence: Regarding the patients with integrase mutations, all had reduced susceptibility to raltegravir and elvitegravir , and one patient, additionally to dolutegravir (DTG) and bictegravir. Table 1 II Mutation entries include: Accessory G163R/G163K/E157Q and Major E138K.

Rationale: The integrase-resistance mutations reported across individuals were G163R, G163K, E157Q, and E138K.

Answer: G163R, G163K, E157Q, E138K


Question: 6101 

Evidence: Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20] for protease (PR), reverse transcriptase (RT) and integrase mutations. In this study, we found a high rate of mutations in HIV-infected patients with LLV by proviral DNA amplification.

Rationale: The paper reports genotypic resistance interpretation only; it does not describe any phenotypic susceptibility test method.

Answer: NA


Question: 6102 

Evidence: Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20]. We could amplify and obtain successful genotypes for RT and PR segment in 15/16 patients (94 %), and in 16/ 16 patients for integrase segment.

Rationale: No IC50/IC90 values are presented; only genotypic predictions are reported.

Answer: No


Question: 6103 

Evidence: Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20]. Fig. 1 explains the distribution of these mutations.

Rationale: There are no fold-change IC50 data; the study provides only mutation-based resistance interpretations.

Answer: No


Question: 6104 

Evidence: Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20] for protease (PR), reverse transcriptase (RT) and integrase mutations, and additionally with Geno2pheno for integrase mutations. 

Rationale: No phenotypic assay was used; only in silico genotypic interpretation tools were applied.

Answer: NA


Question: 6105 

Evidence: In this study, we found a high rate of mutations in HIV-infected patients with LLV by proviral DNA amplification. Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20].

Rationale: The paper does not report replication capacity measurements.

Answer: No


Question: 6106 

Evidence: Consensus sequence was analyzed and interpreted in Stanford University HIV drug resistance database [20]. Regarding the patients with integrase mutations, all had reduced susceptibility to raltegravir and elvitegravir , and one patient, additionally to dolutegravir (DTG) and bictegravir.

Rationale: No phenotypic susceptibility testing was performed; hence no drugs were tested phenotypically.

Answer: NA


Question: 7101 

Evidence: After DNA extraction and amplification [19], sequencing was made in Macrogen laboratories (U.S.A) by Sanger method. We included patients with confirmed HIV infection, currently attending medical controls at Red Salud UC CHRISTUS.

Rationale: The study sequenced patient-derived proviral DNA without constructing site-directed mutants.

Answer: No


Question: 7102 

Evidence: As RNA genotyping test has a high possibility to deliver inconsistent results in patients with LLV [12], proviral DNA emerges as an alternative to study drug resistance mutations (DRM) in these patients. After DNA extraction and amplification [19], sequencing was made in Macrogen laboratories (U.S.A) by Sanger method.

Rationale: There are no in vitro passage experiments; the work is based on direct sequencing of patient samples.

Answer: No